All in Filtration Membranes: The Journey of a Leader in the Upstream Sector of Life Sciences
Exclusive interview with Jia Qijun, founder of Aileos
Time：
2026-05-21 20:23
Author：
xieyijun
Autoimmune CAR-T: On the Eve of Realization
The First Autoimmune CAR-T to Submit a BLA
Time：
2026-05-21 08:13
Author：
xieyijun
Innovative Drugs Go Global: A BD Frenzy, Yet Few Drug Approvals
How Can the NMPA Increase Its Authority in the Global Market?
Time：
2026-05-20 08:11
Author：
xieyijun
CPIC 2026 | Nanobody Drug R&D Session Agenda Released
Discussing the Future of Nanobodies with Industry Pioneers
Time：
2026-05-19 13:11
Author：
xieyijun
Fangtuo Bio Secures Its Position in the Hundred-Billion-Ophthalmology Gene Therapy Track
Domestic AAV Breaks the Deadlock in Severe Ophthalmic Diseases
Time：
2026-05-19 08:17
Author：
xieyijun
CPIC 2026丨CNS Novel Drug R&D Session Schedule Released
We look forward to joining you in this intellectual feast of CNS research and development.
Time：
2026-05-18 16:01
Author：
xieyijun
CPIC 2026 | Suzhou Industrial Park Satellite Session: Going Global & BD Transaction Dialogue
jointly explore paths for high-quality development
Time：
2026-05-18 13:56
Author：
xieyijun
Time：
2026-05-17 18:21
Author：
xieyijun
Recommended content
mRNA tumor vaccine "seller", entering a golden age
When a Biotech company that has been acquired achieves rare growth
AI、 Cold bench and puzzle, when will 'one person, one seedling' come to an end?
This road is long, but the threshold has already been crossed.
The "economic accounts" of immunology business development are being rewritten
After rejecting a $30 billion acquisition offer, a biotech company has emerged as a giant
determination for independence
联系我们
同写意
写意宣发
同写意Biotech
同写意微服务